OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Adding CAR T-Cell Therapy to the Electronic Medical Record

February 28th 2020

Andrea Price, APN, discusses adding CAR T-cell therapy to the electronic medical record.

Dr. Joshi on Durvalumab/RT Combo in Locally Advanced Urothelial Cancer

February 28th 2020

Monika Joshi, MD, discusses durvalumab (Imfinzi) and radiation therapy (DUART) in locally advanced urothelial cancer of the bladder.

Dr. Shapiro on the Surgical Management of Advanced-Stage Melanoma

February 28th 2020

Richard L. Shapiro, MD, discusses the surgical management of advanced-stage melanoma.

Dr. Gibbs on the Lack of Treatment Options in Sarcoma

February 27th 2020

C. Parker Gibbs Jr, MD, discusses the lack of treatment options for patients with soft tissue and bone sarcomas.

Dr. Rossetti on Symptom Management for MPNs

February 27th 2020

James M. Rossetti, DO, discusses symptom management for patients with myeloproliferative neoplasms.

Dr. Pemmaraju on Methods to Treat Anemia in MPNs

February 27th 2020

Naveen Pemmaraju, MD, discusses methods to address anemia in patients with myelodysplastic syndromes.

Dr. Kremyanskaya on Unmet Needs in Myelofibrosis

February 27th 2020

Marina Kremyanskaya, MD, PhD, discusses unmet needs in myelofibrosis.

Dr. McKay on a Real-World Analysis of Radium-223 in mCRPC

February 27th 2020

Rana R. McKay, MD, discusses the results of a real-world analysis of radium-223 in patients with metastatic castration-resistant prostate cancer.

Dr. Agarwal on Developing Biomarkers of Response to Cabozantinib/Atezolizumab in mCRPC

February 27th 2020

Neeraj Agarwal, MD, discusses the importance of developing biomarkers of response to the combination of cabozantinib and atezolizumab in patients with metastatic castration-resistant prostate cancer.

Dr. Graff on Results of the KEYNOTE-199 Trial in mCRPC

February 27th 2020

Julie N. Graff, MD, discusses the results of the phase II KEYNOTE-199 trial in metastatic castration-resistant prostate cancer.

Dr. Oh on Remaining Challenges With Prostate Cancer Treatment

February 27th 2020

William K. Oh, MD, discusses remaining challenges with the advancing treatments in prostate cancer.

Dr. Grivas on Comparisons Between ATM and BRCA1/2 Mutations in mCRPC

February 27th 2020

Petros Grivas, MD, discusses comparisons between ATM and BRCA1/2 mutations in metastatic castration-resistant prostate cancer.

Dr. Snyder on Transplant Updates in Myelofibrosis

February 26th 2020

David S. Snyder, MD, discusses updates in treating patients with myelofibrosis who undergo transplant.

Dr. Kuykendall on the Approval of Fedratinib in Myelofibrosis

February 26th 2020

Andrew T. Kuykendall, MD, discusses the additionof fedratinib to the treatment paradigm in myelofibrosis.

Dr. Garcia on the Tolerability of Navitoclax/Ruxolitinib in Myelofibrosis

February 26th 2020

Jacqueline S. Garcia, MD, discusses the tolerability of the combination of navitoclax plus ruxolitinib in patients with myelofibrosis.

Dr. Goldman on Targeted Therapy Options for EGFR-, ALK-, and ROS1-Mutated NSCLC

February 26th 2020

Jonathan W. Goldman, MD, discusses targeted therapy options for patients with EGFR-, ALK-, and ROS1-mutated non–small cell lung cancer.

Dr. Wolpin on the CCGA Study of Blood-Based Testing for Early Detection of GI Cancers

February 26th 2020

Brian M. Wolpin, MD, MPH, discusses the GI subgroup findings of the Circulating Cell-Free Genome Atlas study.

Dr. Brahmer on Targeting Driver Mutations in NSCLC

February 26th 2020

Julie R. Brahmer, MD, discusses targeted treatments for patients with oncogene-driven non–small cell lung cancer.

Dr. Daver on Azacitidine and Nivolumab in Acute Myeloid Leukemia

February 26th 2020

Naval G. Daver, MD, discusses the rationale of azacitidine and nivolumab in acute myeloid leukemia.

Dr. Blum on the Current Treatment Landscape of Acute Myeloid Leukemia

February 26th 2020

William G. Blum, MD, discusses the current treatment landscape of acute myeloid leukemia.